Record-high sales and growth in operating profit
First written in FY2022-Q3. 12 of 15 entries say "Advanced", first in FY2022. Latest entry: FY2026.
The whole theme swung hardest in 2017: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Company achieved a new record high* as the new HOPECELL storage plan gained traction in its domestic business and orders remained steady.」
Sales in the first year of consolidation were ¥2,811.344 million, which the Company explained was a new record high compared with the standalone results of the filing company before consolidation. - FY2026-H1AdvancedAnnual report
「Sales in the second quarter from July to September reached a new quarterly record high, following the first quarter, and cumulative sales for the interim consolidated accounting period also reached a record high.」
Second-quarter sales reached a new quarterly record high, and cumulative interim sales also reached a record high. Sales for the interim consolidated accounting period were ¥1,415.094 million. - FY2025AdvancedAnnual report
「As a result of these activities, sales for the fiscal year were ¥2,679.175 million, up 8.0% year on year; operating profit was ¥418.509 million, up 1.1%; ordinary profit was ¥428.773 million, up 2.8%; and net profit was ¥385.796 million, up 24.1%. All metrics reached new record highs, but actual results fell short of the full-year earnings forecast, partly because the new HOPECELL plan took time to gain traction.」
Sales, operating profit, ordinary profit and net profit all reached new record highs, but the HOPECELL plan took time to gain traction, resulting in performance below the full-year forecast. - FY2025-H1AdvancedAnnual report
「As a result, all metrics, including the number of stored specimens, comprising umbilical cords and umbilical cord blood, sales and profit at each stage, reached new record highs. Sales for the interim accounting period were a record-high ¥1,373.816 million, up 13.2% year on year; operating profit was ¥258.060 million, up 19.9%; ordinary profit was ¥264.063 million, up 22.1%; and interim net profit was ¥271.954 million, up 70.2%.」
Sales, operating profit, ordinary profit and interim net profit for the interim accounting period exceeded the previous year's levels, and all metrics, including the number of stored specimens, reached new record highs. - FY2024-Q3AdvancedAnnual report
「As a result of these activities, sales for the cumulative third-quarter period were ¥1,884.907 million, up 19.4% year on year; operating profit was ¥356.235 million, up 36.2%; ordinary profit was ¥358.401 million, up 36.1%; and quarterly net profit was ¥254.981 million, up 48.0%. Each figure reached a record high.」
Sales, operating profit, ordinary profit and quarterly net profit for the cumulative third-quarter period each reached a record high and increased year on year. - FY2024-Q2AdvancedAnnual report
「As a result of these activities, sales for the cumulative second-quarter period reached a record high of ¥1,213.559 million, up 17.1% year on year. Operating profit was ¥215.292 million, up 31.4%; ordinary profit was ¥216.307 million, up 31.1%; and quarterly net profit was ¥159.791 million, up 45.1%.」
For the cumulative second-quarter period, sales reached a record high of ¥1,213.559 million, while operating profit, ordinary profit and quarterly net profit also increased year on year. - FY2024-Q1AdvancedAnnual report
「As a result of these activities, sales for the cumulative first-quarter period reached a record high of ¥577.108 million, up 17.1% year on year. Operating profit was ¥88.605 million, up 20.1%; ordinary profit was ¥90.761 million, up 22.1%; and quarterly net profit was ¥75.686 million, up 49.6%, reflecting the recording of a ¥22.327 million gain on the sale of investment securities as extraordinary income following the listing of investment company Cuorips Inc. on the TSE Growth Market on 27 June of this year, among other factors.」
Sales for the cumulative first-quarter period reached a record high of ¥577.108 million. Operating profit was ¥88.605 million, ordinary profit was ¥90.761 million and quarterly net profit was ¥75.686 million. Each profit figure also increased year on year. - FY2023AdvancedAnnual report
「As a result of these activities, sales for the fiscal year reached a record high of ¥2,091.293 million, up 17.4% year on year. Operating profit was ¥297.560 million, up 31.1%, and ordinary profit was ¥300.365 million, up 41.3%.」
Full-year sales reached a record high of ¥2,091.293 million, operating profit was ¥297.560 million and ordinary profit was ¥300.365 million, all up year on year. - FY2023-Q3AdvancedAnnual report
「As a result of these activities, sales for the cumulative third-quarter period reached a record high of ¥1,579.198 million, up 19.9% year on year. Operating profit was ¥261.514 million, up 55.4%; ordinary profit was ¥263.397 million, up 71.6%; and quarterly net profit was ¥172.293 million, up 76.5%.」
Sales for the cumulative third-quarter period reached a record high, while operating profit, ordinary profit and quarterly net profit also increased year on year. - FY2023-Q2AdvancedAnnual report
「As a result of these activities, sales for the cumulative second-quarter period reached a record high of ¥1,036.409 million, up 19.8% year on year. Operating profit was ¥163.889 million, up 48.5%; ordinary profit was ¥164.962 million, up 73.6%; and quarterly net profit was ¥110.145 million, up 80.7%.」
For the cumulative second-quarter period, sales reached a record high of ¥1,036.409 million, and operating profit, ordinary profit and quarterly net profit all increased year on year. - FY2023-Q1AdvancedAnnual report
「As a result of these activities, sales for the cumulative first-quarter period reached a record high of ¥492.837 million, up 16.2% year on year. Operating profit was ¥73.802 million, up 46.7%; ordinary profit was ¥74.322 million, up 96.8%; and quarterly net profit was ¥50.605 million, up 114.6%.」
Sales for the cumulative first-quarter period reached a record high of ¥492.837 million. Operating profit was ¥73.802 million, ordinary profit was ¥74.322 million and quarterly net profit was ¥50.605 million. Year on year, the increases in these profit figures were 46.7%, 96.8% and 114.6%, respectively. - FY2022AdvancedAnnual report
「As a result of these activities, sales for the fiscal year reached a record high of ¥1,781.943 million, an increase of ¥372.428 million, or 26.4%, from the previous fiscal year. Operating profit was ¥226.952 million, an increase of ¥140.072 million, or 161.2%.」
For the full fiscal year, sales reached a record high of ¥1,781.943 million and operating profit was ¥226.952 million, representing year-on-year increases of 26.4% and 161.2%, respectively. - FY2022-Q3First statedAnnual report
「As a result of these activities, sales for the cumulative third-quarter period reached a record high of ¥1,316.683 million, up 23.7% year on year, while operating profit was ¥168.267 million, up 85.5%.」
For the cumulative third-quarter period, the Company reported record-high sales and operating profit up 85.5% year on year.